Two pharmaceutical companies that make the abortion pill mifepristone filed emergency requests with the Supreme Court on Saturday, asking the justices to block a Fifth Circuit ruling that bars doctors from prescribing the drug through telehealth or dispensing it by mail. The filings came just one day after a three-judge panel sided with Louisiana and imposed a temporary nationwide injunction reinstating a 2021 requirement that mifepristone be prescribed and dispensed in person.
Delaware-based Danco Laboratories, which manufactures the brand-name version Mifeprex, sought what it called an "immediate administrative stay" to freeze the appeals court order while the Supreme Court weighs a full appeal. GenBioPro, the second manufacturer, filed its own emergency appeal the same day, as The Hill reported.
The speed of the filings tells you something about the stakes, and about how far the legal landscape around mifepristone has shifted since the Supreme Court's 2022 Dobbs decision returned abortion policy to the states.
On Friday, the three-judge panel ruled in favor of Louisiana in its case against the Food and Drug Administration. The panel's temporary nationwide injunction reinstates the in-person prescribing and dispensing requirement that had been in place before the FDA, under former President Biden, permanently removed it. That removal happened roughly 18 months before the Supreme Court's 2024 decision on mifepristone access.
Louisiana officials argued that the FDA's loosened rules made it easier for abortion pills to be mailed into states where the procedure is mostly banned. The state has even attempted to prosecute out-of-state doctors for providing abortion drugs via mail to in-state residents.
That is the heart of the matter. After Dobbs, states gained the authority to regulate abortion within their borders. Louisiana exercised that authority. The FDA's decision to strip away the in-person dispensing requirement, made under the Biden administration, effectively allowed a workaround: pills shipped by mail, telehealth prescriptions crossing state lines, and a distribution model that made state-level restrictions harder to enforce.
The Fifth Circuit's ruling puts the guardrails back in place, at least temporarily. Whether the Supreme Court will let that stand is the open question.
Lawyers for Danco described the Fifth Circuit's order as "unprecedented" and "extremely disruptive." In their May 2 filing, they warned of what they called "regulatory whiplash."
Danco's lawyers told the Court:
"The panel's ruling injects immediate confusion and upheaval into highly time-sensitive medical decisions, and it forces Danco, FDA, certified Mifeprex providers, patients, and pharmacies all to guess at what is allowed and what is not."
They also wrote that the order "forces patients, providers, and pharmacies into immediate uncertainty, with no transition period and no practical guidance." The framing is designed to pressure the justices into acting fast, presenting the ruling as chaos rather than a return to a regulatory standard that existed for more than two decades.
GenBioPro CEO Evan Masingill struck a more combative tone in a statement to The Hill:
"The Supreme Court must reject this unfounded and baseless attack on an essential medication."
Masingill added that his company "firmly believes all people have a right to access safe, affordable, evidence-based health care" and expressed concern that "anti-abortion special interests are attempting to undermine the US Food and Drug Administration's regulatory authority."
That line, about undermining FDA authority, deserves scrutiny. The FDA approved mifepristone in 2000. For years afterward, the agency maintained the in-person dispensing requirement. The Biden-era decision to remove that requirement was the regulatory change. The Fifth Circuit's ruling restores the prior status quo. Calling a return to longstanding rules an "attack" on the FDA is a stretch, and it reveals how much of this fight is about preserving a policy outcome rather than defending regulatory principle.
This is not the first time mifepristone has landed on the Supreme Court's emergency docket. In 2024, the justices upheld access to the drug, unanimously rejecting a challenge from anti-abortion doctors on the grounds that they lacked legal standing. That decision did not reach the merits of the FDA's regulatory choices, it simply closed the door on one set of plaintiffs.
Louisiana's case is different. The state is a regulator with clear standing, and it is challenging the specific FDA actions that loosened distribution rules after Dobbs. The Supreme Court has dealt with Louisiana in other high-profile contexts this term, and the justices are no strangers to emergency applications from the state.
The mifepristone dispute also raises broader questions about FDA authority and the limits of executive-branch rulemaking, questions that carry weight far beyond abortion policy. When an agency removes a safety-related dispensing requirement by administrative action, and a state argues that the change undermines its own duly enacted laws, the tension between federal regulatory power and state sovereignty is real.
The Washington Free Beacon has noted that the challenged lower-court rulings would have sharply limited access to mifepristone, a drug used in more than half of U.S. abortions and also for miscarriage management. That statistic helps explain why the pharmaceutical companies moved so quickly, and why the political reaction was immediate.
Sen. Patty Murray (D-Wash.) wasted no time. She wrote on social media:
"The Fifth Circuit just told millions of women that three judges know better than the FDA, their doctors, and 25 years of evidence. They don't. I have no intention of letting this stand."
Murray's framing, three judges versus millions of women, is politically effective but legally misleading. The three-judge panel did not ban mifepristone. It reinstated an in-person dispensing requirement that existed for most of the drug's history. The question before the court was not whether the drug should exist but how it should be distributed, and whether the FDA's decision to allow mail-order distribution overrode state laws restricting abortion.
That distinction matters. The political rhetoric around this case consistently collapses a narrow regulatory question into a sweeping access narrative. The Supreme Court's recent decisions have reshaped multiple policy battlefields, and abortion is no exception. But conflating a dispensing rule with a ban serves political purposes, not legal clarity.
The Supreme Court now faces a familiar choice: act quickly to stay the Fifth Circuit's order, or let the injunction take effect while the case proceeds through normal channels. The justices have shown a willingness to intervene on mifepristone before. But the legal posture is different this time. Louisiana's standing is stronger than the anti-abortion doctors who brought the 2024 case, and the merits question, whether the FDA exceeded its authority, remains unresolved.
The names of the three judges on the Fifth Circuit panel have not been publicly identified in the filings described so far. Nor is there a clear timeline for when the Supreme Court will respond to the emergency applications. Those gaps matter. The speed of the Court's response will signal how seriously the justices take the manufacturers' claims of immediate harm.
For states like Louisiana that have enacted restrictions on abortion, the Fifth Circuit ruling represents something straightforward: the federal judiciary recognizing that when the FDA loosens drug-distribution rules in ways that undercut state law, states have a right to push back. The real-world consequences of federal court orders on state governance are not abstract, they play out in enforcement, in elections, and in the daily operations of state agencies.
The mifepristone manufacturers want the Supreme Court to freeze that pushback before it takes hold. Whether the justices oblige will say a great deal about where the Court draws the line between federal regulatory convenience and the authority the Dobbs decision returned to the states.
Mifepristone was prescribed and dispensed in person for more than twenty years. The constitutional questions surrounding federal overreach did not begin with this case, and they will not end with it. But calling a return to established practice "unprecedented" tells you more about the people making the argument than about the rule they are fighting.
If the FDA's own longstanding safety requirements are now treated as an intolerable burden the moment they inconvenience a preferred policy outcome, the word "regulation" has lost its meaning.